This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Stock Market News for Apr 11, 2024
by Zacks Equity Research
Wall Street closed sharply lower on Wednesday, in a broad-based slump.
Insiders Are Buying These 5 Stocks
by Derek Lewis
Many investors closely monitor insider buys, as they can provide meaningful insight into the longer-term picture of a company. And recently, they've been deploying cash for these five stocks.
Walgreens Boots Alliance, Inc. (WBA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Walgreens (WBA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Herbalife and Amazon
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Herbalife and Amazon have been highlighted in this Industry Outlook article.
2 Retail Pharmacy Stocks to Watch and One to Avoid Amid Industry Headwinds
by Urmimala Biswas
Zacks Retail-Pharmacies and Drug Stores industry players like CVS and WBA are likely to gain despite reimbursement challenges that are hurting the overall health industry. HLF might face the wrath of economic challenges.
Company News for Apr 1, 2024
by Zacks Equity Research
Companies In The News Are: RH, AMC, CC, WBA.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Walgreens Boots (WBA) Q2 Earnings Top Estimates, EPS View Down
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.
Compared to Estimates, Walgreens (WBA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Walgreens (WBA) give a sense of how its business performed in the quarter ended February 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Walgreens Boots Alliance (WBA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 46.34% and 2.29%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Walgreens (WBA) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Walgreens (WBA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended February 2024.
Nike, Lululemon, Carnival and Walgreens are part of Zacks Earnings Preview
by Zacks Equity Research
Nike, Lululemon, Carnival and Walgreens are highlights of the Zacks Earnings Preview article.
Looking Ahead to Q1 Earnings
by Sheraz Mian
2024 Q1 earnings are expected to be up +2.4% from the same period last year on +3.4% higher revenues, which would pencil in the third consecutive period of positive earnings growth. But what else should investors expect?
Walgreens Boots Alliance (WBA) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Walgreens Boots Alliance (WBA) stood at $20.58, denoting a -1.06% change from the preceding trading day.
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $20.80, marking a -1.38% move from the previous day.
Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens (WBA) fiscal second-quarter performance is likely to benefit from strong growth in the United States and the International front
Earnings Preview: Walgreens Boots Alliance (WBA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA
by Zacks Equity Research
Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.
Walgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) reachead $20.82 at the closing of the latest trading day, reflecting a +0.97% change compared to its last close.
Walgreens Boots Alliance, Inc. (WBA) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Walgreens (WBA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Walgreens Boots Alliance (WBA) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $21.28, marking a -1.21% move from the previous day.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.
Should You Invest in the Invesco S&P 500 Equal Weight Consumer Staples ETF (RSPS)?
by Zacks Equity Research
Sector ETF report for RSPS
Walgreens Boots Alliance (WBA) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Walgreens Boots Alliance (WBA) stood at $20.89, denoting a -0.57% change from the preceding trading day.
Is Invesco S&P 500 Equal Weight Consumer Staples ETF (RSPS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPS